Literature DB >> 10322651

Experimental study on intramuscular injection of eukaryotic expression vector pcDNA3- IL-6 on BXSB mice.

G Yang1, H Liu, M Jiang, X Jiang, S Li, Y Yuan, D Ma.   

Abstract

OBJECTIVE: To study the role of IL-6 in systemic lupus erythematosis (SLE).
METHODS: We constructed eukaryotic expression vector pcDNA3- IL-6 encoding for IL-6 and injected it intramuscularly into BXSB mice. 22 of the 3.5-month-old male BXSB mice were divided into two groups. One group was injected with the pcDNA3-IL-6 100 micrograms per mouse twice at the interval of 20 days. Another group was injected with plasmid pcDNA3 at the same time as control. The ANA and proteinuria were monitored every 10 days, and the IL-6 activity in serum, IgG, C3 deposition and IL-6 expression in kidney detected at the 40th day.
RESULTS: IL-6 encoding plasmid had harmful effects on murine SLE with increased ANA level, proteinuria, IgG, C3 deposition and IL-6 expression in kidney, but there was no difference of serum GPT levels between the two groups.
CONCLUSION: Excessive production of IL-6 could play an important pathogenic role in SLE. Blocking or reducing IL-6 secretion might be a new therapy for SLE.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10322651

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  6 in total

1.  Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study.

Authors:  Gabor G Illei; Yuko Shirota; Cheryl H Yarboro; Jimmy Daruwalla; Edward Tackey; Kazuki Takada; Thomas Fleisher; James E Balow; Peter E Lipsky
Journal:  Arthritis Rheum       Date:  2010-02

2.  Interleukin-6 gene polymorphism in Iranian patients with systemic lupus erythematosus.

Authors:  Esmaeil Moazemi Godarzi; Eskandar Kamali Sarvestani; Elham Aflaki; Zahra Amirghofran
Journal:  Clin Rheumatol       Date:  2010-04-11       Impact factor: 2.980

Review 3.  Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications.

Authors:  Natasha Jordan; David D'Cruz
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-12       Impact factor: 5.346

Review 4.  Rationale for interleukin-6 blockade in systemic lupus erythematosus.

Authors:  E Tackey; P E Lipsky; G G Illei
Journal:  Lupus       Date:  2004       Impact factor: 2.911

Review 5.  Novel therapeutic agents in clinical development for systemic lupus erythematosus.

Authors:  Natasha Jordan; Pamela M K Lutalo; David P D'Cruz
Journal:  BMC Med       Date:  2013-05-03       Impact factor: 8.775

Review 6.  Current and emerging treatment options in the management of lupus.

Authors:  Natasha Jordan; David D'Cruz
Journal:  Immunotargets Ther       Date:  2016-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.